Q3-osavuosiraportti
13 päivää sitten‧1 t 2 min
0,0723 USD/osake
Viimeisin osinko
Tarjoustasot
Määrä
Osto
208
Myynti
Määrä
372
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
24,87VWAP
Alin
24,22VaihtoMäärä
34,3 3 215 572
VWAP
Ylin
24,87Alin
24,22VaihtoMäärä
34,3 3 215 572
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Yhtiökokous | 5.6. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2024 Vuosiraportti | 5.2. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8.11.TEVA now in clear progress. PART 1 The post is long. I mostly wrote it for myself, to get an overview and put down my thoughts, but I'm happy to share it with you here on the page. - No obligation to read. TEVA has put the unpleasant matters behind it. Targeted efforts are being made to reduce the previously enormous, bankruptcy-threatening debt for the company to a net debt/EBITDA ratio of under 2.0x by 2027 at the latest (according to Gurufocus) as part of the long-term financial strategy. According to Marketscreener, Net Debt2025 = 12644 usd and EBITDA2025 = 4960, which gives a ratio of 2.55. So the company is well on its way to meeting that goal. Kåre Schultz was, as is well known, CEO of Teva from 2017 to 2022. He primarily focused on restructuring, cost reduction, and stabilization of Teva's finances. Richard Francis took over as CEO in January 2023 and introduced the "Pivot to Growth" strategy in May 2023. Teva's "Pivot to Growth" strategy is about shifting focus from generic drugs to innovation and growth through new, advanced medical products. There are four central pillars in the strategy: • Strengthen the portfolio of innovative drugs, especially with products such as AUSTEDO (for involuntary movements). Sales in 2025 have increased by 38% year-over-year, making AUSTEDO Teva's fastest-growing brand. The substance contributes significantly to the EBITDA improvement. The goal is to achieve over 2.5 billion USD in annual revenues from AUSTEDO alone by 2027. Teva has raised its 2025 expectation to 2.05–2.15 billion USD, and CEO Richard Francis has stated that they are on track for 2.5 billion USD in 2027. AJOVY (for migraine). Teva expects 630–640 million USD in AJOVY revenue for the full year 2025. Expected growth +19% in local currency compared to 2024 UZEDY (for schizophrenia; active substance Risperidone). UZEDY has the potential to reach 600,000 patients with schizophrenia, thanks to its long-acting and differentiated profile. Teva expects total revenue of 190–200 million USD for the full year 2025. The number of patients in treatment is not precisely stated, but prescription growth has increased by 119% year-over-year. • Expand pipeline with groundbreaking treatments for diseases such as migraine, schizophrenia, and inflammatory bowel disease. Teva invests in first-class and groundbreaking drugs in: Schizophrenia: Olanzapine LAI. Phase 3 completed, but it has not yet been approved by the authorities. Teva expects to submit an application for approval (NDA) by the end of 2025. If approved, it will be the first long-acting olanzapine without a PDSS warning (Post-Injection Delirium/Sedation Syndrome), which is an important differentiating factor. Asthma: ICS/SABA in Phase 3 Inflammatory bowel disease: Anti-TL1A. Teva's and Sanofi's anti-TL1A antibody for inflammatory bowel disease (IBD), called duvakitug, is entering Phase 3. The study is expected to start in the second half of 2025. Approval could happen around 2027–2028, depending on regulatory processes. Teva and Sanofi collaborate on development and commercialization in an agreement worth up to 1.5 billion USD for Teva. Teva sees duvakitug as a potential blockbuster. The global market for the treatment of inflammatory bowel disease (IBD) is estimated at approx. 28 billion USD in 2025 and is expected to grow to 47 billion USD in 2034. Analysts estimate that the TL1A class combined could amount to 5–10 billion USD annually, depending on approvals and competition. If duvatikug achieves 20–30% of the TL1A market, it corresponds to 1–3 billion USD in annual revenue – enough for blockbuster status. Teva and Sanofi share 50/50.
6.11.6.11.Anus Analysis: new 5-year target price for Teva: 100 $
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
13 päivää sitten‧1 t 2 min
0,0723 USD/osake
Viimeisin osinko
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8.11.TEVA now in clear progress. PART 1 The post is long. I mostly wrote it for myself, to get an overview and put down my thoughts, but I'm happy to share it with you here on the page. - No obligation to read. TEVA has put the unpleasant matters behind it. Targeted efforts are being made to reduce the previously enormous, bankruptcy-threatening debt for the company to a net debt/EBITDA ratio of under 2.0x by 2027 at the latest (according to Gurufocus) as part of the long-term financial strategy. According to Marketscreener, Net Debt2025 = 12644 usd and EBITDA2025 = 4960, which gives a ratio of 2.55. So the company is well on its way to meeting that goal. Kåre Schultz was, as is well known, CEO of Teva from 2017 to 2022. He primarily focused on restructuring, cost reduction, and stabilization of Teva's finances. Richard Francis took over as CEO in January 2023 and introduced the "Pivot to Growth" strategy in May 2023. Teva's "Pivot to Growth" strategy is about shifting focus from generic drugs to innovation and growth through new, advanced medical products. There are four central pillars in the strategy: • Strengthen the portfolio of innovative drugs, especially with products such as AUSTEDO (for involuntary movements). Sales in 2025 have increased by 38% year-over-year, making AUSTEDO Teva's fastest-growing brand. The substance contributes significantly to the EBITDA improvement. The goal is to achieve over 2.5 billion USD in annual revenues from AUSTEDO alone by 2027. Teva has raised its 2025 expectation to 2.05–2.15 billion USD, and CEO Richard Francis has stated that they are on track for 2.5 billion USD in 2027. AJOVY (for migraine). Teva expects 630–640 million USD in AJOVY revenue for the full year 2025. Expected growth +19% in local currency compared to 2024 UZEDY (for schizophrenia; active substance Risperidone). UZEDY has the potential to reach 600,000 patients with schizophrenia, thanks to its long-acting and differentiated profile. Teva expects total revenue of 190–200 million USD for the full year 2025. The number of patients in treatment is not precisely stated, but prescription growth has increased by 119% year-over-year. • Expand pipeline with groundbreaking treatments for diseases such as migraine, schizophrenia, and inflammatory bowel disease. Teva invests in first-class and groundbreaking drugs in: Schizophrenia: Olanzapine LAI. Phase 3 completed, but it has not yet been approved by the authorities. Teva expects to submit an application for approval (NDA) by the end of 2025. If approved, it will be the first long-acting olanzapine without a PDSS warning (Post-Injection Delirium/Sedation Syndrome), which is an important differentiating factor. Asthma: ICS/SABA in Phase 3 Inflammatory bowel disease: Anti-TL1A. Teva's and Sanofi's anti-TL1A antibody for inflammatory bowel disease (IBD), called duvakitug, is entering Phase 3. The study is expected to start in the second half of 2025. Approval could happen around 2027–2028, depending on regulatory processes. Teva and Sanofi collaborate on development and commercialization in an agreement worth up to 1.5 billion USD for Teva. Teva sees duvakitug as a potential blockbuster. The global market for the treatment of inflammatory bowel disease (IBD) is estimated at approx. 28 billion USD in 2025 and is expected to grow to 47 billion USD in 2034. Analysts estimate that the TL1A class combined could amount to 5–10 billion USD annually, depending on approvals and competition. If duvatikug achieves 20–30% of the TL1A market, it corresponds to 1–3 billion USD in annual revenue – enough for blockbuster status. Teva and Sanofi share 50/50.
- 6.11.6.11.Anus Analysis: new 5-year target price for Teva: 100 $
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
208
Myynti
Määrä
372
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
24,87VWAP
Alin
24,22VaihtoMäärä
34,3 3 215 572
VWAP
Ylin
24,87Alin
24,22VaihtoMäärä
34,3 3 215 572
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Yhtiökokous | 5.6. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2024 Vuosiraportti | 5.2. |
Datan lähde: Morningstar, Quartr
Q3-osavuosiraportti
13 päivää sitten‧1 t 2 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 30.7. | |
| 2025 Yhtiökokous | 5.6. | |
| 2025 Q1-osavuosiraportti | 7.5. | |
| 2024 Vuosiraportti | 5.2. |
Datan lähde: Morningstar, Quartr
0,0723 USD/osake
Viimeisin osinko
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8.11.TEVA now in clear progress. PART 1 The post is long. I mostly wrote it for myself, to get an overview and put down my thoughts, but I'm happy to share it with you here on the page. - No obligation to read. TEVA has put the unpleasant matters behind it. Targeted efforts are being made to reduce the previously enormous, bankruptcy-threatening debt for the company to a net debt/EBITDA ratio of under 2.0x by 2027 at the latest (according to Gurufocus) as part of the long-term financial strategy. According to Marketscreener, Net Debt2025 = 12644 usd and EBITDA2025 = 4960, which gives a ratio of 2.55. So the company is well on its way to meeting that goal. Kåre Schultz was, as is well known, CEO of Teva from 2017 to 2022. He primarily focused on restructuring, cost reduction, and stabilization of Teva's finances. Richard Francis took over as CEO in January 2023 and introduced the "Pivot to Growth" strategy in May 2023. Teva's "Pivot to Growth" strategy is about shifting focus from generic drugs to innovation and growth through new, advanced medical products. There are four central pillars in the strategy: • Strengthen the portfolio of innovative drugs, especially with products such as AUSTEDO (for involuntary movements). Sales in 2025 have increased by 38% year-over-year, making AUSTEDO Teva's fastest-growing brand. The substance contributes significantly to the EBITDA improvement. The goal is to achieve over 2.5 billion USD in annual revenues from AUSTEDO alone by 2027. Teva has raised its 2025 expectation to 2.05–2.15 billion USD, and CEO Richard Francis has stated that they are on track for 2.5 billion USD in 2027. AJOVY (for migraine). Teva expects 630–640 million USD in AJOVY revenue for the full year 2025. Expected growth +19% in local currency compared to 2024 UZEDY (for schizophrenia; active substance Risperidone). UZEDY has the potential to reach 600,000 patients with schizophrenia, thanks to its long-acting and differentiated profile. Teva expects total revenue of 190–200 million USD for the full year 2025. The number of patients in treatment is not precisely stated, but prescription growth has increased by 119% year-over-year. • Expand pipeline with groundbreaking treatments for diseases such as migraine, schizophrenia, and inflammatory bowel disease. Teva invests in first-class and groundbreaking drugs in: Schizophrenia: Olanzapine LAI. Phase 3 completed, but it has not yet been approved by the authorities. Teva expects to submit an application for approval (NDA) by the end of 2025. If approved, it will be the first long-acting olanzapine without a PDSS warning (Post-Injection Delirium/Sedation Syndrome), which is an important differentiating factor. Asthma: ICS/SABA in Phase 3 Inflammatory bowel disease: Anti-TL1A. Teva's and Sanofi's anti-TL1A antibody for inflammatory bowel disease (IBD), called duvakitug, is entering Phase 3. The study is expected to start in the second half of 2025. Approval could happen around 2027–2028, depending on regulatory processes. Teva and Sanofi collaborate on development and commercialization in an agreement worth up to 1.5 billion USD for Teva. Teva sees duvakitug as a potential blockbuster. The global market for the treatment of inflammatory bowel disease (IBD) is estimated at approx. 28 billion USD in 2025 and is expected to grow to 47 billion USD in 2034. Analysts estimate that the TL1A class combined could amount to 5–10 billion USD annually, depending on approvals and competition. If duvatikug achieves 20–30% of the TL1A market, it corresponds to 1–3 billion USD in annual revenue – enough for blockbuster status. Teva and Sanofi share 50/50.
- 6.11.6.11.Anus Analysis: new 5-year target price for Teva: 100 $
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
208
Myynti
Määrä
372
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
24,87VWAP
Alin
24,22VaihtoMäärä
34,3 3 215 572
VWAP
Ylin
24,87Alin
24,22VaihtoMäärä
34,3 3 215 572
Välittäjätilasto
Dataa ei löytynyt